跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 328 条关于
“hyaluronidase-tqjs”
全部
328
临床试验
184
药物
41
机构
0
资讯
103
2年前
FDA Approves Subcutaneous Atezolizumab (Tecentriq Hybreza) for Multiple Cancer Types
去年
FDA Approves Subcutaneous Atezolizumab (Tecentriq Hybreza) for Multiple Cancers
2年前
FDA Approves Subcutaneous Tecentriq Hybreza for Multiple Cancer Types
2年前
FDA Approves Roche's Tecentriq Hybreza, a Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
2年前
FDA Approves Roche's Tecentriq Hybreza, a Subcutaneous PD-L1 Inhibitor, for Multiple Cancers
2年前
FDA Approves Genentech's Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Immunotherapy
11个月前
FDA Approves Genentech's Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
去年
Oncology Drug Development Pipeline Remains Robust, Driven by Novel Therapies and Cell Therapies
7个月前
Hyaluronidase Co-Administration Enhances Cancer Immunotherapy Efficacy Through Subcutaneous Delivery
去年
Subcutaneous Immunoglobulin with Hyaluronidase Shows Promise for Idiopathic Inflammatory Myositis Treatment
第 1 页,共 11 页
上一页
下一页